Mar 30, 2026 08:01AM
Mar 30, 2026 08:00AM
Jan 9, 2026 06:01AM
Nov 12, 2025 04:01PM
Oct 17, 2025 04:47AM
Oct 17, 2025 12:52AM
Oct 16, 2025 04:05PM Kezar Life Sciences explores strategic alternatives after FDA setback
Oct 16, 2025 04:05PM
Aug 13, 2025 04:01PM
Jul 15, 2025 04:41PM
Jul 15, 2025 04:41PM
May 13, 2025 04:01PM
Mar 25, 2025 07:30AM
Mar 25, 2025 07:30AM Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter
Dec 2, 2024 06:45AM
Nov 12, 2024 04:01PM
Oct 4, 2024 05:00PM
Oct 4, 2024 05:00PM
Sep 30, 2024 11:33AM
Sep 30, 2024 08:30AM
Sep 30, 2024 08:30AM Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
Nov 10, 2022 04:01PM
Oct 3, 2022 04:01PM
Oct 3, 2022 04:01PM
Jun 28, 2022 09:11AM
Jun 27, 2022 06:01PM
Aug 23, 2021 07:03AM
Aug 23, 2021 07:01AM Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
Aug 12, 2021 04:02PM
Mar 11, 2021 04:01PM
Nov 5, 2020 04:01PM
Oct 23, 2020 07:04AM
Oct 23, 2020 07:00AM
Dec 19, 2019 07:00AM
May 7, 2019 04:05PM Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All